Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers (Q38795742)

6 September 2017

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers (English)

1 reference

6 September 2017

0 references

0 references

12

1 reference

Giovanni Battista Migliori

6 September 2017

6

0 references

Markus Maeurer

object named as

Markus Maeurer

2

0 references

Soumya Swaminathan

10

object named as

Soumya Swaminathan

1 reference

6 September 2017

3

Peter Mwaba

1 reference

6 September 2017

11

Michael Hoelscher

1 reference

6 September 2017

Robert S Wallis

1

1 reference

6 September 2017

Jeremiah Chakaya

4

1 reference

6 September 2017

Roxana Rustomjee

5

1 reference

6 September 2017

Ben Marais

7

1 reference

6 September 2017

Marco Schito

8

1 reference

6 September 2017

Gavin Churchyard

9

1 reference

6 September 2017

language of work or name

1 reference

1 April 2016

1 reference

Lancet Infectious Diseases

6 September 2017

1 reference

6 September 2017

16

1 reference

6 September 2017

4

1 reference

6 September 2017

e34-46

1 reference

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

A four-month gatifloxacin-containing regimen for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tubercu

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Absorption, distribution and retention of the riminocompounds in the experimental animal

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Imipenem for treatment of tuberculosis in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Towards host-directed therapies for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Advancing host-directed therapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Chronic obstructive airways disease following treated pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Mortality after anti-tuberculosis treatment completion: results of long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Longevity loss among cured tuberculosis patients and the potential value of prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Metformin as adjunct antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Neutrophil-Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Toward a unified biosignature for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Are microRNAs suitable biomarkers of immunity to tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Clinical immunology and multiplex biomarkers of human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Validation of analytic methods for biomarkers used in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Imaging in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

A blood RNA signature for tuberculosis disease risk: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

The mechanism of action of PA-824: Novel insights from transcriptional profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Delamanid for multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Prioritized current unmet needs for antibacterial therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

Tackling the tuberculosis epidemic in sub-Saharan Africa--unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900070-0

7 January 2021

10.1016/S1473-3099(16)00070-0

Identifiers

DOI

1 reference

6 September 2017

1 reference